2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Venous Thromboembolism
22
Neoplasms
15
Pulmonary Embolism
10
Venous Thrombosis
9
Thrombosis
6
Multiple Myeloma
4
Upper Extremity Deep Vein Thrombosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Lymphoma
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Mesenteric Ischemia
1
Leukemia
1
Head and Neck Neoplasms
1
Interventions
edoxaban
1
apixaban
1
Warfarin
1
Rivaroxaban
1
Heparin, Low-Molecular-Weight
1
Dalteparin
1
Dabigatran
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Embolism
×
apixaban
×
Clear all
NCT04618913
2026-05-26
VICTORIE
Pfizer
Active not recruiting
1 enrolled